Modern options in personalized therapy of metastatic cutaneous melanoma

A great progress was recently achieved in metastatic melanoma therapy. New targeted therapies allow high efficacy expectations for personalized treatment approaches. BRAF-inhibitors significantly increase time to progression, overall survival and response rate in malignant melanoma patients. Vemurafenib is the first registered in Russia drug of this type. Current clinical data review on vemurafenib is presented in this paper.